VDPHL01 - could it be the replacement to DHT blockers? 3/25/2026
VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
community Most Promising Future Hair Loss Treatments In 2026
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
community Pp405 full presentation on new topical
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
community Upcoming and current hair growth stimulants (2026)
The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.
community Will you guys be trying the time-release oral minoxidil when it comes out?
People are discussing the potential benefits and drawbacks of a new time-release oral minoxidil (VDPHL01) for hair loss, with considerations about its cost, efficacy, and side effects compared to current treatments like 2.5mg doses and topical applications. Some users express interest in trying it if it proves effective and affordable, while others are cautious due to potential side effects or are satisfied with their current regimen.
Related Research
4 / 4 resultsresearch Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research 76221 Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment
research 76626 Adjunctive Combined Regenerative Technique (CRT) vs Oral Minoxidil Alone for Androgenetic Alopecia: A Six-Month Retrospective Study
CRT is more effective than oral minoxidil alone for treating hair loss.